Claims for Patent: 10,272,144

Summary for Patent: 10,272,144

Title:	Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
Abstract:	Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed.
Inventor(s):	Kieber-Emmons; Thomas (Little Rock, AR), Pashov; Anastas (Little Rock, AR), Karbassi; Behjatolah (Little Rock, AR)
Assignee:	BioVentures, LLC (Little Rock, AR)
Application Number:	14/908,503
Patent Claims:	1. A method of treating a human who has been diagnosed as having breast cancer, wherein the breast cancer is selected from the group consisting of i) triple negative breast cancer and ii) breast cancer that is HER2 positive, the method comprising administering to said human a composition comprising a compound having the structure of Formula 1: Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Al- a-Trp-Thr-Leu-Lys-Ala-Ala-dAla-NH.sub.2 Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is cyclohexylalanine, a modified L configuration Alanine shown as CHAla. 2. The method of claim 1 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy. 3. The method of claim 1 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab. 4. The method of claim 1, wherein a) the composition further comprises an anti-cancer chemotherapeutic or anti-cancer radioactive agent, or b) the composition is a component in a kit comprising a first container that comprises the composition and a second container comprising an anti-cancer chemotherapeutic or anti-cancer radioactive agent. 5. The method of claim 1 wherein the composition further comprises an adjuvant. 6. The method of claim 5 wherein the adjuvant is selected from the group consisting of an oil and surfactant adjuvant and QS21 adjuvant. 7. The method of claim 5 wherein the adjuvant is an oil and surfactant adjuvant, wherein the oil is mineral oil and the surfactant is mannide monooleate. 8. The method of claim 1 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g. 9. The method of claim 1 wherein the human is further treated with surgery and/or chemotherapy. 10. The method of treating a human who has been diagnosed as having triple negative breast cancer, the method comprising administering to said human a composition comprising a compound having the structure of Formula 1: Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Al- a-Trp-Thr-Leu-Lys-Ala-Ala-dAla-NH.sub.2 Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is cyclohexylalanine, a modified L configuration Alanine shown as CHAla. 11. The method of claim 10 wherein the human is also treated with surgery and/or chemotherapy. 12. The method of claim 10 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab. 13. The method of claim 1 wherein the human is identified as having a tumor that is HER2 positive. 14. The method of claim 13 further comprising treating the human with chemotherapy. 15. The method of claim 14 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab. 16. The method of claim 7 wherein the human is further treated with surgery and/or chemotherapy. 17. The method of claim 7 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab. 18. A method of treating a human who has been diagnosed as having triple negative breast cancer, the method comprising administering to said human a composition comprising: a compound having the structure of Formula 1: Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Al- a-Trp-Thr-Len-Lys-Ala-Ala-dAla-NH.sub.2 Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is Cyclohexylalanine, a modified L configuration Alanine shown as CHAla, and an oil and surfactant adjuvant, wherein the oil is mineral oil and the surfactant is mannide monooleate. 19. The method of claim 18 wherein the human is also treated with surgery and/or chemotherapy. 20. The method of claim 18 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab. 21. The method of claim 7 wherein the human is identified as having a tumor that is HER2 positive. 22. The method of claim 21 further comprising treating the human with chemotherapy. 23. The method of claim 22 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab. 24. The method of claim 10 wherein the human who has been diagnosed as having triple negative breast cancer has been diagnosed as having metastatic triple negative breast cancer. 25. The method of claim 18 wherein the human who has been diagnosed as having triple negative breast cancer has been diagnosed as having metastatic triple negative breast cancer. 26. The method of claim 11 wherein the human is also treated with chemotherapy and surgery. 27. The method of claim 11 comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel. 28. The method of claim 27 wherein the human is also treated with surgery. 29. The method of claim 13 comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel. 30. The method of claim 13 wherein said breast cancer that is HER2 positive is metastatic. 31. The method of claim 19 wherein the human is also treated with chemotherapy and surgery. 32. The method of claim 19 comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel. 33. The method of claim 32 wherein the human is also treated with surgery. 34. The method of claim 21, further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel. 35. The method of claim 21 wherein said breast cancer that is HER2 positive is metastatic. 36. The method of claim 10 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy. 37. The method of claim 10 wherein composition further comprises adjuvant. 38. The method of claim 37 wherein adjuvant is selected from the group consisting of an oil and surfactant adjuvant and QS21 adjuvant. 39. The method of claim 10 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g. 40. The method of claim 18 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy. 41. The method of claim 18 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g. 42. The method of claim 7 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy. 43. The method of claim 7 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g.

Details for Patent 10,272,144

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-07-31
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-07-31
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2033-07-31
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2033-07-31